Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cytopia Limited
Cytopia Commences Second Phase II Study in Brain Cancer
September 16th, 2008
Cytopia Limited announced that it is commencing enrolment for its Phase Ib/II study of CYT997, the company's novel vascular-disrupting anticancer agent, in patients with an aggressive form of brain cancer known as glioblastoma multiforme (GBM). The GBM clinical trial is the first Phase II efficacy study in highly vascular, solid tumor indications for the company and the second in its suite of Phase II studies designed to investigate the anticancer activity of CYT997. Patient recruitment to the study will now commence, following regulatory approval in Australia and the United States. The clinical study will investigate the activity of CYT997 in...
Source: Cancer Weekly (2008-09-16)
|
